Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Harvard Bioscience (HBIO) Short-Term Debt repayments (2021 - 2025)

Harvard Bioscience (HBIO) has disclosed Short-Term Debt repayments for 4 consecutive years, with $2.0 million as the latest value for Q2 2024.

  • On a quarterly basis, Short-Term Debt repayments fell 30.51% to $2.0 million in Q2 2024 year-over-year; TTM through Mar 2025 was $2.0 million, a 77.09% decrease, with the full-year FY2024 number at $2.6 million, down 76.71% from a year prior.
  • Short-Term Debt repayments was $2.0 million for Q2 2024 at Harvard Bioscience, up from $500000.0 in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $4.0 million in Q1 2021 to a low of -$1.8 million in Q4 2021.
  • A 4-year average of $2.0 million and a median of $2.5 million in 2023 define the central range for Short-Term Debt repayments.
  • Peak YoY movement for Short-Term Debt repayments: soared 197.22% in 2022, then crashed 80.0% in 2024.
  • Harvard Bioscience's Short-Term Debt repayments stood at -$1.8 million in 2021, then skyrocketed by 197.22% to $1.8 million in 2022, then skyrocketed by 42.86% to $2.5 million in 2023, then dropped by 18.0% to $2.0 million in 2024.
  • Per Business Quant, the three most recent readings for HBIO's Short-Term Debt repayments are $2.0 million (Q2 2024), $500000.0 (Q1 2024), and $2.5 million (Q4 2023).